Claims
- 1. The compound L-thyroxine-5′-isoprenyl-MPA.
- 2. The compound 5′-[(digoxigenin-3-yl)-β-amidomethyl-MPA.
- 3. The compound 4′-[(digoxigenin-3-yl)-oxymethylcarbonyl-DADOO-carbonylmethyl-MPA.
- 4. The compound 5′-[(digoxigenin-3-yl)-oxymethylcarbonyl-DADOO-carbonylmethyl-MPA.
- 5. The compound 5′-[(theophylline-8-butyramidoethylaminocarbonyloxy)isoprenyl]-MPA.
- 6. A conjugate of a drug or drug derivative and an uncompetitive inhibitor of IMPDH.
- 7. The conjugate of claim 6, wherein the uncompetitive inhibitor is mycophenolic acid or a mycophenolic acid analog.
- 8. The conjugate of claim 6, wherein the drug is digoxigenin.
- 9. The conjugate of claim 6, wherein the drug is theophylline.
- 10. A conjugate of a hormone and an uncompetitive inhibitor of IMPDH.
- 11. The conjugate of claim 10, wherein the uncompetitive inhibitor is mycophenolic acid or a mycophenolic acid analog.
- 12. The conjugate of claim 10, wherein the hormone is thyroxine.
- 13. A conjugate of a nucleotide and an uncompetitive inhibitor of IMPDH.
- 14. The conjugate of claim 13, wherein the uncompetitive inhibitor is mycophenolic acid or a mycophenolic acid analog.
- 15. A conjugate of a polypeptide and an uncompetitive inhibitor of IMPDH.
- 16. The conjugate of claim 15, wherein the uncompetitive inhibitor is mycophenolic acid or a mycophenolic acid analog.
- 17. A ligand-inhibitor conjugate with the structure
- 18. The conjugate of claim 17 wherein n=1.
- 19. The conjugate of claim 18 wherein x=digoxigenin-3-yl-oxymethylcarbonyl-DADOO.
- 20. The conjugate of claim 18 wherein x=3-amino-digoxigenin.
- 21. A ligand-inhibitor conjugate with the structure
- 22. The conjugate of claim 21 wherein x=digoxigenin-3-yl-oxymethylcarbonyl-DADOO.
- 23. A ligand-inhibitor conjugate with the structure
- 24. The conjugate of claim 23 wherein x is —O—CONH—(CH2)2—NH-thyroxine.
- 25. The conjugate of claim 23 wherein x is —O—CONH—(CH2)2—NHC(═O)—(CH2)4-theophylline.
- 26. The conjugate of claim 23 wherein x is
- 27. The conjugate of claim 6, wherein the drug is phenytoin.
- 28. The conjugate of claim 6, wherein the drug is gentamicin.
- 29. The conjugate of claim 6, wherein the drug is digoxin or a digoxin analog.
- 30. The conjugate of claim 6, wherein the drug is digitoxin or a digitoxin analog.
- 31. The conjugate of claim 23 wherein X is —NH—CO—(CH2)3-phenytoin.
- 32. The conjugate of claim 23 wherein X is —O—CO[NH-gentamicin].
- 33. The conjugate of claim 23 wherein X is —NH—CO—Ph—CO[NH-gentamicin] and Ph is phenyl.
- 34. The conjugate of claim 23 wherein X is 5′-[[[(digoxin(1,4-oxazepin))-4-yl]-phenyl-4-carbonyl]amino]-.
- 35. The conjugate of claim 23 wherein X is 5′-[[[(digitoxin(1,4-oxazepin))-4-yl]-phenyl-4-carbonyl]amino]-.
- 36. A ligand-inhibitor with the structure
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This is a continuation-in-part of U.S. application Ser. No. 09/603,646 filed Jun. 26, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60141098 |
Jun 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09603646 |
Jun 2000 |
US |
Child |
10341692 |
Jan 2003 |
US |